An update of the recombinant protein expression systems of Cyanovirin-N and challenges of preclinical development.

Conclusion: To produce pharmaceutically effective CVN, we first need to identify the best expression system, with Escherichia coli, Pichia pastoris , Lactic acid bacteria and transgenic plants being possible candidates. For this reason, heterologous production of this valuable protein is a serious challenge. Since different obstacles influence clinical trials on microbicides in the field of HIV prevention, these items should be considered for evaluating the CVN activity in pre-clinical and clinical studies. PMID: 29977835 [PubMed]
Source: BioImpacts - Category: Research Tags: Bioimpacts Source Type: research